Trial Profile
A Phase I/II Study of the PD-1 Antibody Nivolumab in Combination With Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Nivolumab (Primary) ; Aspirin
- Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 15 Jun 2023 Results assessing the toxicity and preliminary efficacy of the combination in patients with relapsed HL and LBCL presented at the 28th Congress of the European Haematology Association
- 01 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 01 Mar 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.